Baird raised the firm’s price target on Mirum Pharmaceuticals (MIRM) to $88 from $80 and keeps an Outperform rating on the shares. The firm updated its model following its Blujay acquisition which brings in an attractive opportunity in HDV.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Strategic Acquisition Positions Mirum Pharmaceuticals for Leadership in Rare Liver Disease Market
- Strategic Acquisition and Market Potential Drive Buy Rating for Mirum Pharmaceuticals
- Mirum Pharmaceuticals price target raised to $94 from $89 at Evercore ISI
- Mirum’s deal for Bluejay a positive readthrough to Vir, says Needham
- Mirum Pharmaceuticals price target raised to $130 from $95 at Cantor Fitzgerald